相关实验视频

Updated: Jan 15, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

定量节点负担作为化疗效益的预测标记在术后的囊腺癌:一个多机构基于人群的研究

Zheng Li¹, Chongyuan Sun¹, Zefeng Li¹

¹Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Frontiers in immunology

|October 6, 2025

概括

辅助化疗 (ACT) 对囊腺癌患者具有高结节负担 (LODDS>-1.4) 的生存益处. 这一发现有助于为这种罕见的癌症做出个性化治疗决策.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
手术瘤学手术瘤学

背景情况:

在囊性腺癌 (AA) 中辅助化疗 (ACT) 的有效性尚未明确.
在AA中最佳的患者选择ACT仍然不清楚.

研究的目的:

评估ACT在囊性腺癌 (AA) 患者中的有效性.
根据节点负担确定受益于ACT的患者子组.

主要方法:

从中国和西方的SEER注册处进行治疗切除的AA患者的回顾性分析.
使用积极淋巴结的日志概率 (LODDS) 评估的定量节点负担.
考克斯回归模型用于评估生存结果 (OS,RFS,CSS) 和与ACT的相互作用.

主要成果:

在未被选择的AA患者中,ACT并没有显著改善生存率.
超过-1.4的LODDS患者在ACT治疗中显著延长了生存时间.
增加LODDS与ACT的更大生存益处相关,与N分类不同.

结论:

LODDS是个性化ACT决策的宝贵工具,用于囊腺癌.
节点负担量化可以指导ACT选择,以改善患者的治疗结果.

关键词:

有很多货物.辅助性化疗是一种辅助性化疗.囊性腺癌细胞瘤.化疗的好处是化疗的好处.淋巴结负担增加了淋巴结的负担.幸存率幸存率生存率

更多相关视频

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频